Portal de Periódicos da CAPES

The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct

2018; Elsevier BV; Volume: 206; Linguagem: Inglês

10.1016/j.ahj.2018.07.012

1097-6744

Philip Joseph, Prem Pais, Antonio L Dans, Jackie Bosch, Denis Xavier, Patricio López‐Jaramillo, Khalid Yusoff, Anwar Santoso, Shamim Hayder Talukder, Habib Gamra, Karen Yeates, Paul Camacho López, Jessica Tyrwhitt, Peggy Gao, Koon Teo, Salim Yusuf,

Pharmaceutical Economics and Policy

It is hypothesized that in individuals without clinical cardiovascular disease (CVD), but at increased CVD risk, a 50% to 60% reduction in CVD risk could be achieved using fixed dose combination (FDC) therapy (usually comprised of multiple blood-pressure agents and a statin [with or without aspirin]) in a single "polypill". However, the impact of a polypill in preventing clinical CV events has not been evaluated in a large randomized controlled trial.